Position in INDV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$108,936,860
New position
Shares Held
3,574,044
first reported quarter
Ownership
2.93%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in INDV
reported options exposure · as of Mar 31, 2026CallValue
$2,243,328
CallShares
73,600
PutValue
$1,749,552
PutShares
57,400
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $928,363,116 across 59 Drug Manufacturers - Specialty & Generic names. INDV ranks #2 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
360,643 | $213,854,086 | |
| 2 | INDV |
Indivior Pharmaceuticals, Inc.
This page
|
3,574,044 | $108,936,860 | |
| 3 | ELAN |
Elanco Animal Health Inc
|
4,387,127 | $104,983,948 | |
| 4 | ALKS |
Alkermes plc.
|
2,241,584 | $79,262,409 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
1,493,446 | $77,196,223 | |
| 6 | ZTS |
Zoetis Inc.
|
501,011 | $59,224,510 | |
| 7 | VTRS |
Viatris Inc
|
3,993,155 | $53,947,523 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
474,750 | $22,859,212 |
All Filings in INDV
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,749,552 | 57,400 | Put | Defined | 2026-05-15 | |
| 2026-03-31 | $2,243,328 | 73,600 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $108,936,860 | 3,574,044 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||